KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Liabilities (2016 - 2025)

Biomarin Pharmaceutical's Other Non-Current Liabilities history spans 17 years, with the latest figure at $150.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 17.07% year-over-year to $150.8 million, compared with a TTM value of $150.8 million through Dec 2025, up 17.07%, and an annual FY2025 reading of $150.8 million, up 17.07% over the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $150.8 million at Biomarin Pharmaceutical, down from $163.1 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $163.1 million in Q3 2025, with the low at $15.2 million in Q4 2021.
  • Average Other Non-Current Liabilities over 5 years is $102.5 million, with a median of $105.5 million recorded in 2023.
  • Year-over-year, Other Non-Current Liabilities tumbled 86.72% in 2021 and then surged 559.43% in 2022.
  • Tracing BMRN's Other Non-Current Liabilities over 5 years: stood at $15.2 million in 2021, then surged by 559.43% to $100.0 million in 2022, then rose by 19.92% to $119.9 million in 2023, then rose by 7.41% to $128.8 million in 2024, then increased by 17.07% to $150.8 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Other Non-Current Liabilities are $150.8 million (Q4 2025), $163.1 million (Q3 2025), and $148.8 million (Q2 2025).